Clinical trials
Placebo - Control clinical trials
Below are recruiting placebo - control clinical trials, each written for real people, not researchers. We’re tracking 3,962 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07699120Enrolling by invitationPhase 1
Testing BRC-002 safety in healthy volunteers
This trial checks how safe BRC-002 is in healthy people and how it affects the body with and without food. It helps researchers understand the right dose and any side effects.
Toronto, OntarioAges 18–55 - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Birmingham, AlabamaAges 18 years+ - NCT07169279RecruitingPhase 2
Study of infigratinib for children under 3 with achondroplasia
This trial tests an oral medication called infigratinib to see if it can help young children with achondroplasia. It is for children under 3 years old who have a confirmed genetic diagnosis.
Oakland, CaliforniaAges birth–2.7 years - NCT06742996RecruitingPhase 3
Sonrotoclax plus zanubrutinib for relapsed mantle cell lymphoma
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
Birmingham, AlabamaAges 18 years+ - NCT06712654RecruitingPhase 2
Testing AP306 for high phosphate in dialysis patients
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Huntsville, AlabamaAges 18 years+ - NCT07274254RecruitingPhase 3
Lidocaine to reduce opioid use for sickle cell pain crisis
This trial tests if adding lidocaine to standard pain treatment can reduce the amount of morphine or oxycodone needed for a severe pain crisis or acute chest syndrome in sickle cell disease. It is for adults in the ICU who have already started opioid treatment within the last 72 hours.
BordeauxAges 18 years+ - NCT05712200RecruitingPhase 3
Abelacimab for atrial fibrillation when blood thinners aren’t suitable
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
Birmingham, AlabamaAges 65 years+ - NCT07525544RecruitingPhase 1
Safety Study of VH4770359 in Healthy Adults
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
Baltimore, MarylandAges 18–55 - NCT04934228RecruitingPhase 1
Study targeting inflammation in people with obesity and high blood pressure
This Phase 1 study looks at a treatment aimed at reducing “inflammation patterns” that are common in obesity and insulin resistance. If you meet specific health and lab criteria, you may be asked to visit a research lab and provide blood samples to see how the treatment affects your body.
Kansas City, KansasAges 18–79 - NCT04945213RecruitingPhase 3
Biperiden to prevent seizures after traumatic brain injury
This trial tests whether biperiden can lower the chance of developing epilepsy after an acute traumatic brain injury (with bleeding or bruising seen on CT). If you qualify, you would get the medicine or a placebo soon after the injury, and researchers will compare outcomes.
Fortaleza, CearáAges 18–75 - NCT04951622RecruitingPhase 3
Testing nipocalimab for adults with generalized myasthenia gravis
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
Paradise Valley, ArizonaAges 18 years+ - NCT04951635RecruitingPhase 3
Almonertinib after chemoradiation for stage III lung cancer
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Ji'nan, ShandongAges 18 years+ - NCT04959201RecruitingPhase 2
NMDA and antioxidant add-on to treat schizophrenia symptoms
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
TaichungAges 18–65 - NCT04959864Recruiting
Food supplement study for sperm DNA damage in men
This trial tests whether a daily food supplement (with myo-inositol, N-acetyl-cysteine, zinc, and vitamins) can reduce sperm DNA damage. It enrolls men with higher-than-normal sperm DNA fragmentation, and it checks semen health during the study.
ParisAges 20–45 - NCT04963777Recruiting
Prebiotics for gut health in young people with type 1 diabetes
This trial studies whether taking prebiotics can change gut bacteria (gut microbiome) in people with type 1 diabetes. The goal is to see if these gut changes are linked to better health or diabetes-related outcomes.
Calgary, AlbertaAges 7 years+ - NCT04965298RecruitingPhase 3
Lansoprazole add-on treatment for idiopathic pulmonary fibrosis
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Norwich, NorfolkAges 40 years+ - NCT04970446RecruitingPhase 1/Phase 2
Fecal transplant to restore gut microbes in Crohn’s
This Phase 1/2 study tests whether a fecal microbiome transplant (FMT) can reduce active inflammation in people with Crohn’s disease. It’s designed for people who currently have signs of active bowel inflammation and can attend regular procedure visits.
Melbourne, VictoriaAges 18–70 - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT04974138RecruitingPhase 4
Preventing first stroke in people with high-risk blood pressure
This trial tests whether a study medicine regimen can help prevent a first stroke in people with hard-to-control “high homocysteine” risk factors linked to a specific gene type. You may qualify if you have certain blood pressure levels, a specific MTHFR gene result, and related blood test findings.
Bengbu, AnhuiAges 45–74 - NCT04974151RecruitingPhase 4
Prevention trial for stroke risk in people with high blood pressure
This trial tests an approach to prevent first-time stroke and heart problems in people with high blood pressure who also have a specific genetic test result (MTHFR 677 TT). It may help by lowering risk before a first stroke happens.
Bengbu, AnhuiAges 45–74 - NCT04976036RecruitingPhase 2
Nintedanib to reduce nosebleeds in adults with HHT
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
BronAges 18 years+ - NCT04982965RecruitingEarly Phase 1
Study brain changes behind cannabis pain relief
This early study looks at how the brain may respond to cannabis to reduce long-lasting lower back pain. You may be asked to follow strict rules about cannabis, opioids, and safety checks (including MRI) to help researchers understand the brain mechanisms.
La Jolla, CaliforniaAges 21–65 - NCT04984512RecruitingPhase 2/Phase 3
Testing mitizodone tablets for major depression symptoms
This trial studies whether mitizodone phosphate tablets can improve symptoms of major depressive disorder (MDD). It also checks the treatment’s safety, including mood and physical health effects.
Dongguan, GuangdongAges 18–65 - NCT04985344RecruitingPhase 3
Propranolol to treat PTSD symptoms in children using memory reactivation
This trial studies whether propranolol (a heart-related medicine) can help children with post-traumatic stress disorder (PTSD) after a special memory-activation session. The goal is to reduce PTSD symptoms compared with the comparison condition.
ToulouseAges 7–12
Hear when a new Placebo - Control trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for placebo - control?
- Yes. Clin2 currently lists 3,962 recruiting placebo - control studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a placebo - control trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a placebo - control trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.